@article{7ad96414a4c74f33a29d4d4f1b62165f,
title = "Generation of a new Adar1p150−/− mouse demonstrates isoform-specific roles in embryonic development and adult homeostasis",
abstract = "The RNA editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) is an essential regulator of the innate immune response to both cellular and viral double-stranded RNA (dsRNA). Adenosine-to-inosine (A-to-I) editing by ADAR1 modifies the sequence and structure of endogenous dsRNA and masks it from the cytoplasmic dsRNA sensor melanoma differentiation-associated protein 5 (MDA5), preventing innate immune activation. Loss-of-function mutations in ADAR are associated with rare autoinflammatory disorders including Aicardi–Gouti{\`e}res syndrome (AGS), defined by a constitutive systemic up-regulation of type I interferon (IFN). The murine Adar gene encodes two protein isoforms with distinct functions: ADAR1p110 is constitutively expressed and localizes to the nucleus, whereas ADAR1p150 is primarily cytoplasmic and is inducible by IFN. Recent studies have demonstrated the critical requirement for ADAR1p150 to suppress innate immune activation by self dsRNAs. However, detailed in vivo characterization of the role of ADAR1p150 during development and in adult mice is lacking. We identified a new ADAR1p150-specific knockout mouse mutant based on a single nucleotide deletion that resulted in the loss of the ADAR1p150 protein without affecting ADAR1p110 expression. The Adar1p150−/− died embryonically at E11.5–E12.5 accompanied by cell death in the fetal liver and an activated IFN response. Somatic loss of ADAR1p150 in adults was lethal and caused rapid hematopoietic failure, demonstrating an ongoing requirement for ADAR1p150 in vivo. The generation and characterization of this mouse model demonstrates the essential role of ADAR1p150 in vivo and provides a new tool for dissecting the functional differences between ADAR1 isoforms and their physiological contributions.",
keywords = "A-to-I RNA editing, ADAR1 isoforms, ADAR1p150, innate immunity, RNA modification, type I interferon",
author = "Zhen Liang and Ankita Goradia and Walkley, {Carl R.} and Heraud-Farlow, {Jacki E.}",
note = "Funding Information: The authors thank S. Taylor and E. Tonkin for technical assistance; R. Dickins (Australian Centre for Blood Disease, Monash University) for p53.1224 shRNA; the Monash Genome Modification Platform (MGMP) at Monash University for the generation of the Adar1L196Cfs (p.L196CfsX6) mice; Monash Antibody Technology Facility (MATF) for purification of ADAR1 antibody from hybridomas; Addgene for plasmid distribution; and St. Vincent{\textquoteright}s Hospital BioResource{\textquoteright}s Centre for the care of experimental animals. The Adar1L196Cfs mutant mice were produced via CRISPR/Cas9 mediated genome editing by the Monash Genome Modification Platform (MGMP), Monash University as a node of Phenomics Australia. Phenomics Australia is supported by the Australian Government Department of Education through the National Collaborative Research Infrastructure Strategy, the Super Science Initiative, and the Collaborative Research Infrastructure Scheme. This work was supported by the National Health and Medical Research Council (NHMRC; APP1183553 to C.R.W. and J.E.H.-F.; APP1182453 to J.E.H.-F.); a Melbourne Research Scholarship (to Z.L. from The University of Melbourne). J.E.H.-F. is supported by a fellowship from 5point Foundation Funding Information: The authors thank S. Taylor and E. Tonkin for technical assistance; R. Dickins (Australian Centre for Blood Disease, Monash University) for p53.1224 shRNA; the Monash Genome Modification Platform (MGMP) at Monash University for the generation of the Adar1 (p.L196CfsX6) mice; Monash Antibody Technology Facility (MATF) for purification of ADAR1 antibody from hybridomas; Addgene for plasmid distribution; and St. Vincent{\textquoteright}s Hospital BioResource{\textquoteright}s Centre for the care of experimental animals. The Adar1 mutant mice were produced via CRISPR/Cas9 mediated genome editing by the Monash Genome Modification Platform (MGMP), Monash University as a node of Phenomics Australia. Phenomics Australia is supported by the Australian Government Department of Education through the National Collaborative Research Infrastructure Strategy, the Super Science Initiative, and the Collaborative Research Infrastructure Scheme. This work was supported by the National Health and Medical Research Council (NHMRC; APP1183553 to C.R.W. and J.E.H.-F.; APP1182453 to J.E.H.-F.); a Melbourne Research Scholarship (to Z.L. from The University of Melbourne). J.E.H.-F. is supported by a fellowship from 5point Foundation and in part by the Victorian State Government Operational Infrastructure Support Scheme to St. Vincent{\textquoteright}s Institute. Publisher Copyright: {\textcopyright} 2023 Liang et al.",
year = "2023",
month = sep,
doi = "10.1261/rna.079509.122",
language = "English",
volume = "29",
pages = "1325--1338",
journal = "RNA",
issn = "1355-8382",
publisher = "Cold Spring Harbor Laboratory Press",
number = "9",
}